Authors
1 Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran
2 Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran
Abstract
Pregnancy termination and abortion‑related complications are well‑established problems among
women at reproductive age and resulted in significant morbidity and mortality. Accordingly, a
systematic study was performed to investigate the economic evaluation studies results on costs
and benefits of medical and surgical abortion methods. PubMed, Web of Science, Scopus, Embase,
Cochrane library, ProQuest, and ScienceDirect databases as well as Google scholar were searched
through June 2021. Original full‑text English language studies that performed an economic evaluation
analysis comparing medical and surgical methods of pregnancy termination were included in this
review. A critical quality assessment was conducted utilizing the Consolidated Health Economic
Evaluation Standards checklist. The latest web‑based tool adjusted the estimates of costs expressed
in one specific currency and price year into a specific target currency (the year 2020 $US). Overall,
538 records were retrieved, and 20 studies were deemed eligible for qualitative synthesis. Among
the reviewed studies, three studies investigated cost‑minimization analysis, three studies investigated
cost‑utility analysis, and 14 studies investigated cost‑effectiveness analysis. The directly comparison
of medical with surgical abortion was most frequently studied. Medical abortion saved US$ 6 to US$
2373 per patient’s costs. Medical abortion was cost‑effective and cost‑saving option in compare to
the surgical abortion across all perspectives (the incremental cost effectiveness ratio ranged from
US$ 419 to US$ 4,044). Quality scores of included studies ranged from 54% to 100%, and 70% of
studies received a score of above 85% and had “excellent” quality. According to the results, based on
various economic and clinical effectiveness decision‑making criteria used in different studies of health
economic evaluation, the majority of research provided evidence on the advantage of pharmaceutical
methods compared to surgical methods, as well as the advantages of using combinations therapy
compared to single therapeutic interventions.
Keywords
Cost‑effectiveness analysis of alternative first‑trimester pregnancy
termination strategies in Mexico City. BJOG 2009;116:768‑79.
2. Cahill N, Sonneveldt E, Stover J, Weinberger M, Williamson J,
Wei C, et al. A probabilistic assessment of trends in modern
contraceptive prevalence, unmet need for and demand satisfied
with modern methods in the countries of the FP2020 initiative. The
Lancet 2018; 391(10123), 870-882.
3. Calhoun BC. Book review: Complications: Abortion’s impact on
women. The Linacre Quarterly. 2018 May;85(2):178.
4. Soleimani Movahed M, Husseini Barghazan S, Askari F,
Arab Zozani M. The economic burden of abortion and its
complication treatment cares: A systematic review. J Family
Reprod Health 2020;14:60‑7.
5. Vlassoff M. Economic impact of unsafe abortion‑related morbidity
and mortality: Evidence and estimation challenges. Vol. 59.
Brighton, UK: Institute of Development Studies, 2008.
6. Smith C, Scott RH, Free C, Edwards T. Characteristics and
contraceptive outcomes of women seeking medical or surgical
abortion in reproductive health clinics in Cambodia. Contracept
Reprod Med 2019;4:1‑9.
7. Nagendra D, Koelper N, Loza‑Avalos SE, Sonalkar S, Chen M,
Atrio J, et al. Cost‑effectiveness of mifepristone pretreatment
for the medical management of nonviable early pregnancy:
Secondary analysis of a randomized clinical trial. JAMA Netw
Open 2020;3:e201594.
8. Shirmohammadi F, Nekuei N, Bahadoran P, Montazery G.
Preconception care in therapeutic abortion applicants. J Educ
Health Promot 2017;6:65.
9. Rausch M, Lorch S, Chung K, Frederick M, Zhang J, Barnhart K.
A cost‑effectiveness analysis of surgical versus medical
management of early pregnancy loss. Fertil Steril 2012;97:355‑60.e1.
10. Whitehouse KC, Kim CR, Ganatra B, Duffy JM, Blum J, Brahmi D,
et al. Standardizing abortion research outcomes (STAR):
A protocol for developing, disseminating and implementing a
core outcome set for medical and surgical abortion. Contraception
2017;95:437‑41.
11. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance
GW. Methods for the Economic Evaluation of Health Care
Programme. United States; Oxford University Press; 2015.
12. HashempourR, Raei B, Safaei Lari M, Abolhasanbeigi Gallezan N,
AkbariSari A. QALY league table of Iran: A practical method for
better resource allocation. Cost Eff Resour Alloc 2021;19:3.
13. Berkley HH, Greene HL, Wittenberger MD. Mifepristone
combination therapy compared with misoprostol monotherapy
for the management of miscarriage: A cost‑effectiveness analysis.
Obstet Gynecol 2020;136:774‑81.
14. Bradley SE, Prata N, Young‑Lin N, Bishai DM. Cost‑effectiveness
of misoprostol to control postpartum hemorrhage in low‑resource
settings. Int J Gynaecol Obstet 2007;97:52‑6.
15. Cubo AM, Soto ZM, Haro‑Pérez A, Hernández Hernández ME,
Doyague MJ, Sayagués JM. Medical versus surgical treatment
of first trimester spontaneous abortion: A cost‑minimization
analysis. PLoS One 2019;14:e0210449.
16. Goranitis I, Lissauer DM, Coomarasamy A, Wilson A,
Daniels J, Middleton L, et al. Antibiotic prophylaxis in the
surgical management of miscarriage in low‑income countries:
A cost‑effectiveness analysis of the AIMS trial. Lancet Glob Health
2019;7:e1280‑6.
17. Graziosi GC, van der Steeg JW, Reuwer PH, Drogtrop AP,
Bruinse HW, Mol BW. Economic evaluation of misoprostol in the
treatment of early pregnancy failure compared to curettage after
an expectant management. Hum Reprod 2005;20:1067‑71.
18. Hu D, Grossman D, Levin C, Blanchard K, Adanu R, Goldie SJ.
Cost‑effectiveness analysis of unsafe abortion and alternative
first‑trimester pregnancy termination strategies in Nigeria and
Ghana. Afr J Reprod Health 2010;14:85‑103.
19. Hunter C, Jensen J, ImeahB, McCarronM, ClarkM. Aretrospective
cost‑effectiveness analysis of mifepristone‑misoprostol medical
abortions in the first year at the Regina general hospital. J Obstet
Gynaecol Can 2021;43:211‑8.
20. Lemmers M, Verschoor MA, Bossuyt PM, Huirne JA, Spinder T,
Nieboer TE, et al. Cost‑effectiveness of curettage vs. expectant
management in women with an incomplete evacuation
after misoprostol treatment for first‑trimester miscarriage:
A randomized controlled trial and cohort study. Acta Obstet
Gynecol Scand 2018;97:294‑300.
21. Lince‑Deroche N, Fetters T, Sinanovic E, Devjee J, Moodley J,
Blanchard K. The costs and cost effectiveness of providing
first‑trimester, medical and surgical safe abortion services
in KwaZulu‑Natal Province, South Africa. PLoS One
2017;12:e0174615.
22. Lubinga SJ, Atukunda EC, Wasswa‑Ssalongo G, Babigumira JB.
Potential cost‑effectiveness of prenatal distribution of misoprostol
for prevention of postpartum Hemorrhage in Uganda. PLoS One
2015;10:e0142550.
23. Niinimäki M, Karinen P, Hartikainen AL, Pouta A. Treating
miscarriages: A randomised study of cost‑effectiveness in medical
or surgical choice. BJOG 2009;116:984‑90.
24. Nwafor JI, Agwu UM, Egbuji CC, Ekwedigwe KC. Misoprostol
versus manual vacuum aspiration for treatment of first‑trimester
incomplete miscarriage in a low‑resource setting: A randomized
controlled trial. Niger J Clin Pract 2020;23:638‑46.
25. Petrou S, TrinderJ, Brocklehurst P, Smith L. Economic evaluation
of alternative management methods of first‑trimester miscarriage
based on results from the MIST trial. BJOG 2006;113:879‑89.
26. Sutherland T, Meyer C, Bishai DM, Geller S, Miller S. Community‑based distribution of misoprostol for treatment
or prevention of postpartum hemorrhage: Cost‑effectiveness,
mortality, and morbidity reduction analysis. Int J Gynaecol Obstet
2010;108:289‑94.
27. VlassoffM, DialloA, PhilbinJ, KostK, BankoleA. Cost‑effectiveness
of two interventions for the prevention of postpartum hemorrhage
in Senegal. Int J Gynaecol Obstet 2016;133:307‑11.
28. Xia W, She S, Lam TH. Medical versus surgical abortion methods
for pregnancy in China: A cost‑minimization analysis. Gynecol
Obstet Invest 2011;72:257‑63.
29. Okeke Ogwulu CB, Williams EV, Chu JJ, Devall AJ, Beeson LE,
Hardy P, et al. Cost‑effectiveness of mifepristone and misoprostol
versus misoprostol alone for the management of missed
miscarriage: An economic evaluation based on the MifeMiso trial.
BJOG 2021;128:1534‑45.
30. Husereau D, Drummond M, Petrou S, Carswell C, Moher D,
Greenberg D, et al. Consolidated health economic evaluation
reporting standards (CHEERS) statement. Int J Technol Assess
Health Care 2013;29:117‑22.
31. Kulier R, Gülmezoglu AM, Hofmeyr GJ, Cheng LN, Campana A.
Medical methods for first trimester abortion. Cochrane Database
Syst Rev. 2004;(1):CD002855.
32. AbouZahr C. Global burden of maternal death and disability. Br
Med Bull 2003;67:1‑11.
33. Low N, Mueller M, Van Vliet HA, Kapp N. Perioperative
antibiotics to prevent infection after first‑trimester abortion.
Cochrane Database Syst Rev 2012;2012:CD005217.
34. El‑Sayed MM, Mohamed SA, Jones MH. Expectant
management of first‑trimester miscarriage. J Obstet Gynaecol
2009;29:681‑5.
)